SCHEMBL12420283

SCHEMBL12420283

CCc1nnc(-c2ccc(B(O)O)cc2)o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.45
NOTUM Q6P988 2/20 0.45
TSHR P16473 2/20 0.45
USP2 O75604 1/20 0.45
POLB P06746 1/20 0.45
LPL P06858 2/20 0.44
LIPG Q9Y5X9 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
NR1H4 Q96RI1 1/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
ALOX12 P18054 1/20 0.40
HPGD P15428 1/20 0.40
GPR55 Q9Y2T6 1/20 0.40
HDAC8 Q9BY41 4/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
MAPK14 Q16539 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12419544 0.87 MAPT (0.61) MAPTNOTUMTSHRUSP2POLB
SCHEMBL12419554 0.84 MAPT (0.51) MAPTNOTUMTSHRUSP2POLB
SCHEMBL12419524 0.83 LPL (0.51) MAPTNOTUMTSHRUSP2POLB
SCHEMBL12419593 0.83 MAPT (0.43) MAPTNOTUMTSHRUSP2POLB
SCHEMBL12419595 0.83 MAPT (0.46) MAPTNOTUMTSHRUSP2POLB
SCHEMBL12419540 0.82 LPL (0.53) MAPTTSHRLPLLIPGALDH1A1
SCHEMBL8050653 0.81 PTGS2 (0.52) MAPTNOTUMTSHRUSP2POLB
SCHEMBL12419606 0.81 NOTUM (0.46) MAPTNOTUMTSHRUSP2POLB
SCHEMBL12419527 0.80 MAPT (0.44) MAPTNOTUMTSHRUSP2POLB
SCHEMBL156353 0.79 KMT2A (0.59) MAPTTSHRUSP2POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 MAPT 3395/4885NOTUM 123/4885TSHR 2563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.